These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2448145)

  • 1. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens.
    Milliken ST; Tattersall MH; Woods RL; Coates AS; Levi JA; Fox RM; Raghavan D
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1645-8. PubMed ID: 2448145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
    van der Gaast A; Verweij J; Planting AS; Stoter G
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):765-8. PubMed ID: 3383976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas.
    Sulkes A; Uziely B; Isacson R; Brufman G; Biran S
    Isr J Med Sci; 1988; 24(9-10):604-10. PubMed ID: 3204009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial.
    Eagan RT; Therneau TM; Rubin J; Long HJ; Schutt AJ
    Am J Clin Oncol; 1987 Feb; 10(1):82-5. PubMed ID: 3548315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Johnson DH; Greco FA
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin.
    Fiore JJ; Kelsen DP; Gralla RJ; Casper ES; Magill G; Cheng E; Ochoa M
    Cancer Treat Rep; 1985 Jun; 69(6):591-4. PubMed ID: 4016765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined 5-fluorouracil, adriamycin and mitomycin C in the management of adenocarcinoma metastasizing to the liver from an unknown primary site.
    al-Idrissi HY
    J Int Med Res; 1990; 18(5):425-9. PubMed ID: 2124191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
    Greco FA; Johnson DH; Hainsworth JD
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with mitomycin C, methotrexate, cisplatin, and vinblastine in the treatment of non-small cell lung cancer.
    Niell HB; Griffin JP; West WH; Neely CL
    Cancer; 1984 Oct; 54(7):1260-3. PubMed ID: 6088022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide.
    Joss RA; Alberto P; Obrecht JP; Barrelet L; Holdener EE; Siegenthaler P; Goldhirsch A; Mermillod B; Cavalli F
    Cancer Treat Rep; 1984 Sep; 68(9):1079-84. PubMed ID: 6090014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
    Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
    Ruckdeschel JC; Finkelstein DM; Ettinger DS; Creech RH; Mason BA; Joss RA; Vogl S
    J Clin Oncol; 1986 Jan; 4(1):14-22. PubMed ID: 3510278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer.
    Niell HB; Griffin JP
    Med Pediatr Oncol; 1985; 13(6):341-5. PubMed ID: 3930930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
    J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
    Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
    J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of disseminated germ cell tumors.
    Einhorn LH
    Cancer; 1987 Aug; 60(3 Suppl):570-3. PubMed ID: 2439185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
    Lele SB; Piver MS
    Gynecol Oncol; 1989 Apr; 33(1):6-8. PubMed ID: 2467845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in metastatic carcinoma of unknown primary.
    Pasterz R; Savaraj N; Burgess M
    J Clin Oncol; 1986 Nov; 4(11):1652-7. PubMed ID: 3095502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.